{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:13:16Z","timestamp":1790871196476,"version":"4.1.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Symbiosis International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04453-y","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:06:10Z","timestamp":1769249170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breast cancer frontiers: mapping molecular signals, intelligent diagnostics, and adaptive therapies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-4675","authenticated-orcid":false,"given":"Dinesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simranjeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Babu","family":"Kondaveeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"4453_CR1","doi-asserted-by":"crossref","unstructured":"Lim YX et al. Breast cancer in asia: Incidence, Mortality, early Detection, mammography Programs, and Risk-Based screening initiatives. Cancers (Basel), 2022. 14(17):4218.","DOI":"10.3390\/cancers14174218"},{"issue":"1","key":"4453_CR2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","volume":"25","author":"M Dong","year":"2025","unstructured":"Dong M, et al. Integration of multi-omics approaches in exploring intra-tumoral heterogeneity. Cancer Cell Int. 2025;25(1):317.","journal-title":"Cancer Cell Int"},{"issue":"23","key":"4453_CR3","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.3390\/ijms252313190","volume":"25","author":"D-K Vo","year":"2024","unstructured":"Vo D-K, Trinh KTL. Emerging biomarkers in metabolomics: advancements in precision health and disease diagnosis. Int J Mol Sci. 2024;25(23):13190.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4453_CR4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cancers17071102","volume":"17","author":"E Carvalho","year":"2025","unstructured":"Carvalho E, et al. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025;17(7):1102.","journal-title":"Cancers"},{"issue":"4","key":"4453_CR5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s12033-024-01133-6","volume":"67","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, et al. From data to cure: A comprehensive exploration of Multi-omics data analysis for targeted therapies. Mol Biotechnol. 2025;67(4):1269\u201389.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"4453_CR6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s12672-025-03254-z","volume":"16","author":"W Ding","year":"2025","unstructured":"Ding W, et al. Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives. Discover Oncol. 2025;16(1):1424.","journal-title":"Discover Oncol"},{"issue":"7","key":"4453_CR7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/ph18070961","volume":"18","author":"H Sabit","year":"2025","unstructured":"Sabit H, et al. Bridging the gap in breast cancer dormancy: Models, Mechanisms, and translational challenges. Pharmaceuticals. 2025;18(7):961.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"4453_CR8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s12672-025-02910-8","volume":"16","author":"S Basu","year":"2025","unstructured":"Basu S, et al. From lab to life: technological innovations in transforming cancer metastasis detection and therapy. Discov Oncol. 2025;16(1):1517.","journal-title":"Discov Oncol"},{"issue":"17","key":"4453_CR9","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers17172938","volume":"17","author":"K Kannan","year":"2025","unstructured":"Kannan K, et al. The underlying mechanisms and emerging strategies to overcome resistance in breast cancer. Cancers. 2025;17(17):2938.","journal-title":"Cancers"},{"key":"4453_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"issue":"1","key":"4453_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13058-025-02068-9","volume":"27","author":"H Sung","year":"2025","unstructured":"Sung H, et al. Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the united States. Breast Cancer Res. 2025;27(1):164.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4453_CR12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1186\/s12885-025-14416-1","volume":"25","author":"W Wang","year":"2025","unstructured":"Wang W, et al. Global, regional, and National burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021. BMC Cancer. 2025;25(1):1015.","journal-title":"BMC Cancer"},{"key":"4453_CR13","doi-asserted-by":"crossref","unstructured":"Sun J, et al. Burden of female diseases among adolescents and young adults aged 10\u201324 years in South Asia and Sub-Saharan Africa, 1990\u20132021: a systematic analysis from the global burden of disease study 2021. Journal of Advanced Research; 2025.","DOI":"10.1016\/j.jare.2025.05.048"},{"issue":"3","key":"4453_CR14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14740\/wjon1278","volume":"11","author":"Z Nasim","year":"2020","unstructured":"Nasim Z, et al. Breast cancer incidence and behavior in younger patients: A study from the Surveillance, epidemiology and end results database. World J Oncol. 2020;11(3):88\u201397.","journal-title":"World J Oncol"},{"issue":"4","key":"4453_CR15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/healthcare12040462","volume":"12","author":"AD Wilkerson","year":"2024","unstructured":"Wilkerson AD, et al. Disparities in breast cancer Care\u2014How factors related to Prevention, Diagnosis, and treatment drive inequity. Healthcare. 2024;12(4):462.","journal-title":"Healthcare"},{"key":"4453_CR16","doi-asserted-by":"crossref","unstructured":"Zhu JW et al. What Is Known about Breast Cancer in Young Women? Cancers, 2023. 15(6): p. 1917.","DOI":"10.3390\/cancers15061917"},{"issue":"1","key":"4453_CR17","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12672-025-03180-0","volume":"16","author":"DK Sharma","year":"2025","unstructured":"Sharma DK, Saripilli R. Recent strategies in diagnosis, screening, prevention, and treatment of breast cancer in young women. Discover Oncol. 2025;16(1):1532.","journal-title":"Discover Oncol"},{"issue":"12","key":"4453_CR18","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.3390\/app15126578","volume":"15","author":"G Calvino","year":"2025","unstructured":"Calvino G, et al. From genomics to AI: revolutionizing precision medicine in oncology. Appl Sci. 2025;15(12):6578.","journal-title":"Appl Sci"},{"issue":"8","key":"4453_CR19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708\u201328.","journal-title":"Cell"},{"issue":"21","key":"4453_CR20","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.3390\/cancers13215552","volume":"13","author":"UM McVeigh","year":"2021","unstructured":"McVeigh UM, Tepper JW, McVeigh TP. A review of breast cancer risk factors in adolescents and young adults. Cancers. 2021;13(21):5552.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40001-023-01618-1","volume":"29","author":"P-C Li","year":"2024","unstructured":"Li P-C, et al. ER-positive and BRCA2-mutated breast cancer: a literature review. Eur J Med Res. 2024;29(1):30.","journal-title":"Eur J Med Res"},{"key":"4453_CR22","doi-asserted-by":"crossref","first-page":"117822342513556","DOI":"10.1177\/11782234251355663","volume":"19","author":"Q Maqsood","year":"2025","unstructured":"Maqsood Q, et al. Recent insights into breast cancer: molecular Pathways, epigenetic Regulation, and emerging targeted therapies. Breast Cancer (Auckl). 2025;19:11782234251355663.","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"4453_CR23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Therapy. 2025;10(1):219.","journal-title":"Signal Transduct Target Therapy"},{"key":"4453_CR24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2020.08.009","volume":"83","author":"G Sher","year":"2022","unstructured":"Sher G, et al. Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications. Sem Cancer Biol. 2022;83:152\u201365.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"4453_CR25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12935-025-03649-6","volume":"25","author":"X Li","year":"2025","unstructured":"Li X, Hu Y, Aslanbeigi F. Genetic and epigenetic alterations in night shift nurses with breast cancer: a narrative review. Cancer Cell Int. 2025;25(1):20.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"4453_CR26","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3390\/cancers12102922","volume":"12","author":"KMT Arif","year":"2020","unstructured":"Arif KMT, et al. Regulatory mechanisms of epigenetic MiRNA relationships in human cancer and potential as therapeutic targets. Cancers. 2020;12(10):2922.","journal-title":"Cancers"},{"key":"4453_CR27","doi-asserted-by":"crossref","unstructured":"Godschalk R, et al. Epigenotoxicity: decoding the epigenetic imprints of genotoxic agents and their implications for regulatory genetic toxicology. Environmental and molecular mutagenesis; 2024.","DOI":"10.1002\/em.22626"},{"issue":"10","key":"4453_CR28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.52403\/ijhsr.20221018","volume":"12","author":"D Das","year":"2022","unstructured":"Das D. Breast cancer classification: A review. Int J Health Sci Res. 2022;12(10):140\u20139.","journal-title":"Int J Health Sci Res"},{"key":"4453_CR29","doi-asserted-by":"crossref","first-page":"632079","DOI":"10.3389\/fphar.2020.632079","volume":"11","author":"M Zubair","year":"2021","unstructured":"Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2021;11:632079.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4453_CR30","first-page":"8904768","volume":"2022","author":"MA Wakili","year":"2022","unstructured":"Wakili MA, et al. Classification of breast cancer histopathological images using densenet and transfer learning. Comput Intell Neurosci. 2022;2022(1):8904768.","journal-title":"Comput Intell Neurosci"},{"issue":"6","key":"4453_CR31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MBC.0000000000000929","volume":"31","author":"J Lou","year":"2020","unstructured":"Lou J, et al. A case-report of two patients with hereditary protein S deficiency treated by Rivaroxaban. Blood Coagul Fibrinolysis. 2020;31(6):405\u20139.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"4453_CR32","doi-asserted-by":"crossref","first-page":"15600","DOI":"10.1038\/s41598-022-19278-2","volume":"12","author":"Z Hameed","year":"2022","unstructured":"Hameed Z, et al. Multiclass classification of breast cancer histopathology images using multilevel features of deep convolutional neural network. Sci Rep. 2022;12(1):15600.","journal-title":"Sci Rep"},{"key":"4453_CR33","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.adcanc.2022.100086","volume":"7","author":"T Tav\u010dar Kunsti\u010d","year":"2023","unstructured":"Tav\u010dar Kunsti\u010d T, Debeljak N, Tacer K. Heterogeneity in hormone-dependent breast cancer and therapy: steroid hormones, HER2, melanoma antigens, and cannabinoid receptors. Adv Cancer Biology - Metastasis. 2023;7:100086.","journal-title":"Adv Cancer Biology - Metastasis"},{"issue":"11","key":"4453_CR34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrc.2017.82","volume":"17","author":"A Sud","year":"2017","unstructured":"Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer. 2017;17(11):692\u2013704.","journal-title":"Nat Rev Cancer"},{"key":"4453_CR35","doi-asserted-by":"crossref","unstructured":"Pereslucha AM et al. Invasive lobular carcinoma: A review of imaging modalities with special focus on pathology concordance. Healthc (Basel), 2023. 11(5):746.","DOI":"10.3390\/healthcare11050746"},{"issue":"7","key":"4453_CR36","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1634\/theoncologist.2018-0363","volume":"24","author":"O Metzger-Filho","year":"2019","unstructured":"Metzger-Filho O, et al. Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade. Oncologist. 2019;24(7):e441\u20139.","journal-title":"Oncologist"},{"issue":"2","key":"4453_CR37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1590\/abd1806-4841.20186806","volume":"93","author":"MG Vallone","year":"2018","unstructured":"Vallone MG, et al. Dermoscopy of inflammatory breast cancer*. An Bras Dermatol. 2018;93(2):289\u201390.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"4453_CR38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1746-1596-7-91","volume":"7","author":"H Haltas","year":"2012","unstructured":"Haltas H, et al. Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report. Diagn Pathol. 2012;7(1):91.","journal-title":"Diagn Pathol"},{"key":"4453_CR39","doi-asserted-by":"crossref","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics, 2023. 15(7):1796.","DOI":"10.3390\/pharmaceutics15071796"},{"key":"4453_CR40","doi-asserted-by":"crossref","first-page":"102246","DOI":"10.1016\/j.tranon.2024.102246","volume":"52","author":"Y Jia","year":"2025","unstructured":"Jia Y, et al. Prognostic prediction for inflammatory breast cancer patients using random survival forest modeling. Translational Oncol. 2025;52:102246.","journal-title":"Translational Oncol"},{"issue":"19","key":"4453_CR41","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.3390\/cancers17193270","volume":"17","author":"K Melan","year":"2025","unstructured":"Melan K, Loap P, Kirova Y. Current perspectives on Non-Metastatic male breast cancer: Genetics, Biology, and treatment advances: A systematic review. Cancers. 2025;17(19):3270.","journal-title":"Cancers"},{"issue":"6","key":"4453_CR42","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/2767-9764.CRC-24-0026","volume":"4","author":"NP Tjader","year":"2024","unstructured":"Tjader NP, et al. Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a Genome-wide study. Cancer Res Commun. 2024;4(6):1597\u2013608.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"4453_CR43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12957-024-03553-9","volume":"22","author":"M Pal","year":"2024","unstructured":"Pal M, Das D, Pandey M. Understanding genetic variations associated with Familial breast cancer. World J Surg Oncol. 2024;22(1):271.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"4453_CR44","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1038\/s41467-020-20173-5","volume":"11","author":"J-W Pan","year":"2020","unstructured":"Pan J-W, et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun. 2020;11(1):6433.","journal-title":"Nat Commun"},{"issue":"4","key":"4453_CR45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44(4):193\u2013207.","journal-title":"Oncogene"},{"key":"4453_CR46","doi-asserted-by":"crossref","unstructured":"De K et al. Role of PARP inhibitors: A new hope for breast cancer therapy. Int J Mol Sci, 2025. 26(6):2773.","DOI":"10.3390\/ijms26062773"},{"key":"4453_CR47","doi-asserted-by":"crossref","unstructured":"Huang Y et al. TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study. Precision Clin Med, 2024. 7(2):pbae009.","DOI":"10.1093\/pcmedi\/pbae009"},{"issue":"7","key":"4453_CR48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/cas.16148","volume":"115","author":"G Bon","year":"2024","unstructured":"Bon G, et al. HER2 mutation as an emerging target in advanced breast cancer. Cancer Sci. 2024;115(7):2147\u201358.","journal-title":"Cancer Sci"},{"key":"4453_CR49","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.ctrv.2024.102861","volume":"132","author":"C Hao","year":"2025","unstructured":"Hao C, et al. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861.","journal-title":"Cancer Treat Rev"},{"key":"4453_CR50","doi-asserted-by":"crossref","unstructured":"Zhu K et al. PI3K\/AKT\/mTOR-Targeted therapy for breast cancer. Cells, 2022. 11(16):2508.","DOI":"10.3390\/cells11162508"},{"key":"4453_CR51","doi-asserted-by":"crossref","first-page":"pe2300406","DOI":"10.1200\/PO.23.00406","volume":"8","author":"J Gong","year":"2024","unstructured":"Gong J, et al. Phase II study of erdafitinib in patients with tumors with FGFR amplifications: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K1. JCO Precis Oncol. 2024;8:pe2300406.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"4453_CR52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/cancers17020234","volume":"17","author":"VK Panda","year":"2025","unstructured":"Panda VK, et al. Molecular insights on signaling cascades in breast cancer: A comprehensive review. Cancers. 2025;17(2):234.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR53","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s12672-025-03764-w","volume":"16","author":"TT Laskar","year":"2025","unstructured":"Laskar TT, et al. Decoding breast cancer: insights into molecular pathways & therapeutic approaches. Discover Oncol. 2025;16(1):2103.","journal-title":"Discover Oncol"},{"key":"4453_CR54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.12.007","volume":"471","author":"S Huang","year":"2020","unstructured":"Huang S, et al. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61\u201371.","journal-title":"Cancer Lett"},{"key":"4453_CR55","doi-asserted-by":"crossref","first-page":"112616","DOI":"10.1016\/j.biopha.2022.112616","volume":"147","author":"T Zhang","year":"2022","unstructured":"Zhang T, et al. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed Pharmacother. 2022;147:112616.","journal-title":"Biomed Pharmacother"},{"key":"4453_CR56","doi-asserted-by":"crossref","unstructured":"Hassan A, Aubel C. The PI3K\/Akt\/mTOR signaling pathway in Triple-Negative breast cancer: A resistance pathway and a prime target for targeted therapies. Cancers (Basel), 2025. 17(13):2232.","DOI":"10.3390\/cancers17132232"},{"issue":"15","key":"4453_CR57","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3390\/cancers15153980","volume":"15","author":"N Choudhary","year":"2023","unstructured":"Choudhary N, et al. Targeting cell signaling pathways in lung cancer by bioactive phytocompounds. Cancers. 2023;15(15):3980.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"1","key":"4453_CR59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Therapy. 2021;6(1):425.","journal-title":"Signal Transduct Target Therapy"},{"issue":"7","key":"4453_CR60","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/medicina61071280","volume":"61","author":"OM Burciu","year":"2025","unstructured":"Burciu OM, et al. Current endocrine therapy in Hormone-Receptor-Positive breast cancer: from tumor biology to the rationale for therapeutic tunning. Medicina. 2025;61(7):1280.","journal-title":"Medicina"},{"issue":"2","key":"4453_CR61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discovery"},{"key":"4453_CR62","doi-asserted-by":"crossref","first-page":"e2100370","DOI":"10.1200\/PO.21.00370","volume":"6","author":"AR Rasti","year":"2022","unstructured":"Rasti AR, et al. PIK3CA mutations drive therapeutic resistance in human epidermal growth factor receptor 2-Positive breast cancer. JCO Precis Oncol. 2022;6:e2100370.","journal-title":"JCO Precis Oncol"},{"key":"4453_CR63","doi-asserted-by":"crossref","first-page":"104404","DOI":"10.1016\/j.critrevonc.2024.104404","volume":"200","author":"M Sirico","year":"2024","unstructured":"Sirico M, et al. Navigating the complexity of PI3K\/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond. Crit Rev Oncol\/Hematol. 2024;200:104404.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"10","key":"4453_CR64","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-010-9208-5","volume":"29","author":"KK Haagenson","year":"2010","unstructured":"Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 2010;29(1):143\u20139.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"4453_CR66","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","volume":"12","author":"L Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez L, et al. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12(1):1786.","journal-title":"Nat Commun"},{"issue":"6","key":"4453_CR67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/ph14060589","volume":"14","author":"KS You","year":"2021","unstructured":"You KS, et al. Potentiating therapeutic effects of epidermal growth factor receptor Inhibition in Triple-Negative breast cancer. Pharmaceuticals. 2021;14(6):589.","journal-title":"Pharmaceuticals"},{"issue":"7","key":"4453_CR68","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.drudis.2016.05.012","volume":"21","author":"T De Marchi","year":"2016","unstructured":"De Marchi T, et al. Endocrine therapy resistance in Estrogen receptor (ER)-positive breast cancer. Drug Discovery Today. 2016;21(7):1181\u20138.","journal-title":"Drug Discovery Today"},{"key":"4453_CR69","doi-asserted-by":"crossref","first-page":"116850","DOI":"10.1016\/j.bcp.2025.116850","volume":"236","author":"P Garg","year":"2025","unstructured":"Garg P, et al. Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for breast cancer therapy. Biochem Pharmacol. 2025;236:116850.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4453_CR70","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell. 2020;183(5):1436\u2013e145631.","journal-title":"Cell"},{"key":"4453_CR71","doi-asserted-by":"crossref","unstructured":"Rascio F et al. The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers (Basel), 2021. 13(16):3949.","DOI":"10.3390\/cancers13163949"},{"issue":"1","key":"4453_CR72","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wang W. Recent progress in immune evasion mechanisms of triple-negative breast cancer. J Translational Med. 2025;23(1):1314.","journal-title":"J Translational Med"},{"issue":"13","key":"4453_CR73","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/cancers17132232","volume":"17","author":"A Hassan","year":"2025","unstructured":"Hassan A, Aubel C. The PI3K\/Akt\/mTOR signaling pathway in Triple-Negative breast cancer: A resistance pathway and a prime target for targeted therapies. Cancers. 2025;17(13):2232.","journal-title":"Cancers"},{"issue":"12","key":"4453_CR74","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/cancers16122259","volume":"16","author":"IM Browne","year":"2024","unstructured":"Browne IM, Okines AFC. Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced Oestrogen-Receptor-Positive breast cancer. Cancers. 2024;16(12):2259.","journal-title":"Cancers"},{"issue":"14","key":"4453_CR75","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"4453_CR76","unstructured":"Aysola K et al. Triple negative breast Cancer - An overview. Hereditary Genet, 2013. 2013(Suppl 2):001."},{"issue":"24","key":"4453_CR77","doi-asserted-by":"crossref","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan L, et al. HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review. Med (Baltim). 2024;103(24):e38508.","journal-title":"Med (Baltim)"},{"key":"4453_CR78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcancer.2023.01.006","volume":"89","author":"S Huang","year":"2023","unstructured":"Huang S, et al. Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective. Semin Cancer Biol. 2023;89:30\u20137.","journal-title":"Semin Cancer Biol"},{"key":"4453_CR79","doi-asserted-by":"crossref","unstructured":"Cheng X. A Comprehensive review of HER2 in cancer biology and therapeutics. Genes (Basel), 2024. 15(7):903.","DOI":"10.3390\/genes15070903"},{"issue":"1","key":"4453_CR80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, et al. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16.","journal-title":"Biomark Res"},{"key":"4453_CR81","doi-asserted-by":"crossref","unstructured":"Quaas M, et al. BRCA1 and BRCA2 gene expression: p53- and cell cycle-dependent repression requires RB and DREAM. Cell Death & Differentiation; 2025.","DOI":"10.1038\/s41418-025-01566-9"},{"issue":"3","key":"4453_CR82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/biology14030253","volume":"14","author":"FP Carbone","year":"2025","unstructured":"Carbone FP, et al. Druggable molecular networks in BRCA1\/BRCA2-Mutated breast cancer. Biology. 2025;14(3):253.","journal-title":"Biology"},{"key":"4453_CR83","doi-asserted-by":"crossref","first-page":"103847","DOI":"10.1016\/j.dnarep.2025.103847","volume":"150","author":"Z Xu","year":"2025","unstructured":"Xu Z, et al. BRCA1 and BRCA2 in DNA damage and replication stress response: insights into their functions, mechanisms, and implications for cancer treatment. DNA Repair (Amst). 2025;150:103847.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"4453_CR84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/dna5020017","volume":"5","author":"N Nguyen","year":"2025","unstructured":"Nguyen N, Arris D, Tran MT. Overview of roles of novel components in the regulation of DNA damage repair in BRCA1-Deficient cancers: an update. DNA. 2025;5(2):17.","journal-title":"DNA"},{"issue":"4","key":"4453_CR85","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","volume":"13","author":"C Marvalim","year":"2023","unstructured":"Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics. 2023;13(4):1421\u201342.","journal-title":"Theranostics"},{"key":"4453_CR86","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","volume":"13","author":"C Marvalim","year":"2023","unstructured":"Marvalim C, Datta A, Lee S. Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics. 2023;13:1421\u201342.","journal-title":"Theranostics"},{"key":"4453_CR87","doi-asserted-by":"crossref","first-page":"110303","DOI":"10.1016\/j.cbi.2022.110303","volume":"369","author":"H Seo","year":"2023","unstructured":"Seo H, et al. Comprehensive analysis of cellular Estrogen signaling in representative Estrogen receptor ligands. Chemico-Biol Interact. 2023;369:110303.","journal-title":"Chemico-Biol Interact"},{"key":"4453_CR88","doi-asserted-by":"crossref","unstructured":"Biason-Lauber A, Lang-Muritano M. Estrogens: Two nuclear receptors, multiple possibilities. Molecular and Cellular Endocrinology, 2022. 554: p. 111710.","DOI":"10.1016\/j.mce.2022.111710"},{"key":"4453_CR89","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fendo.2018.00781","volume":"9","author":"R Girgert","year":"2018","unstructured":"Girgert R, Emons G, Gr\u00fcndker C. Estrogen signaling in ER\u03b1-Negative breast cancer: ER\u03b2 and GPER. Front Endocrinol (Lausanne). 2018;9:781.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"4453_CR90","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.3390\/ijms25158167","volume":"25","author":"J Bartkowiak-Wieczorek","year":"2024","unstructured":"Bartkowiak-Wieczorek J, et al. The dual faces of oestrogen: the impact of exogenous oestrogen on the physiological and pathophysiological functions of tissues and organs. Int J Mol Sci. 2024;25(15):8167.","journal-title":"Int J Mol Sci"},{"key":"4453_CR91","doi-asserted-by":"crossref","unstructured":"Sun MX et al. Role of the Wnt signaling pathway in the complex microenvironment of breast cancer and prospects for therapeutic potential (Review). Int J Oncol, 2025. 66(5):36.","DOI":"10.3892\/ijo.2025.5742"},{"key":"4453_CR92","doi-asserted-by":"crossref","first-page":"116154","DOI":"10.1016\/j.bcp.2024.116154","volume":"223","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, et al. Wnt signaling: modulating tumor-associated macrophages and related immunotherapeutic insights. Biochem Pharmacol. 2024;223:116154.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4453_CR93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","volume":"24","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N. Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation. Mol Cancer. 2025;24(1):107.","journal-title":"Mol Cancer"},{"issue":"25","key":"4453_CR94","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","volume":"28","author":"F Shao","year":"2021","unstructured":"Shao F, Pang X, Baeg GH. Targeting the JAK\/STAT signaling pathway for breast cancer. Curr Med Chem. 2021;28(25):5137\u201351.","journal-title":"Curr Med Chem"},{"key":"4453_CR95","doi-asserted-by":"crossref","unstructured":"Parveen S et al. JAK-STAT Signaling in Autoimmunity and Cancer. ImmunoTargets and Therapy, 2025: pp. 523\u2013554.","DOI":"10.2147\/ITT.S485670"},{"key":"4453_CR96","doi-asserted-by":"crossref","first-page":"821344","DOI":"10.3389\/fphar.2022.821344","volume":"13","author":"B Rah","year":"2022","unstructured":"Rah B, et al. JAK\/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. Front Pharmacol. 2022;13:821344.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4453_CR97","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s12015-025-10893-w","volume":"21","author":"D Kumar","year":"2025","unstructured":"Kumar D, et al. Engineering the future of regenerative medicines in gut health with stem Cell-Derived intestinal organoids. Stem Cell Reviews Rep. 2025;21(5):1449\u201370.","journal-title":"Stem Cell Reviews Rep"},{"key":"4453_CR98","doi-asserted-by":"crossref","first-page":"692173","DOI":"10.3389\/fcell.2021.692173","volume":"9","author":"A Edwards","year":"2021","unstructured":"Edwards A, Brennan K. Notch signalling in breast development and cancer. Front Cell Dev Biology. 2021;9:692173.","journal-title":"Front Cell Dev Biology"},{"key":"4453_CR99","doi-asserted-by":"crossref","unstructured":"Saadh MJ et al. Notch signaling and cancer: Insights into chemoresistance, immune evasion, and immunotherapy. Gene, 2025: p. 149461.","DOI":"10.1016\/j.gene.2025.149461"},{"issue":"3","key":"4453_CR100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/cancers13030369","volume":"13","author":"AS Khatpe","year":"2021","unstructured":"Khatpe AS, et al. Nexus between PI3K\/AKT and Estrogen receptor signaling in breast cancer. Cancers. 2021;13(3):369.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discovery. 2024;10(1):28.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"4453_CR102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13072-024-00554-6","volume":"17","author":"R Prabhakaran","year":"2024","unstructured":"Prabhakaran R, et al. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy. Epigenetics Chromatin. 2024;17(1):31.","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"4453_CR103","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Therapy. 2019;4(1):62.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"4453_CR104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13148-025-01884-2","volume":"17","author":"A Lavoro","year":"2025","unstructured":"Lavoro A, et al. Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective. Clin Epigenetics. 2025;17(1):76.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"4453_CR105","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/genes14051075","volume":"14","author":"M Saviana","year":"2023","unstructured":"Saviana M, et al. Crosstalk between MiRNAs and DNA methylation in cancer. Genes. 2023;14(5):1075.","journal-title":"Genes"},{"key":"4453_CR106","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Mechanisms of HDACs in cancer development. Front Immunol, 2025.16:1529239.","DOI":"10.3389\/fimmu.2025.1529239"},{"issue":"1","key":"4453_CR107","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","volume":"27","author":"M Karami Fath","year":"2022","unstructured":"Karami Fath M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27(1):52.","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"4453_CR108","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncrna.2024.03.013","volume":"9","author":"R Giordo","year":"2024","unstructured":"Giordo R, et al. MicroRNA 21 and long non-coding RNAs interplays underlie cancer pathophysiology: A narrative review. Noncoding RNA Res. 2024;9(3):831\u201352.","journal-title":"Noncoding RNA Res"},{"key":"4453_CR109","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2340\/1651-226X.2024.33008","volume":"63","author":"M Otterlei Fj\u00f8rtoft","year":"2024","unstructured":"Otterlei Fj\u00f8rtoft M, Huse K, Rye IH. The tumor immune microenvironment in breast cancer progression. Acta Oncol. 2024;63:359\u201367.","journal-title":"Acta Oncol"},{"issue":"1","key":"4453_CR110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo Z, et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark Res. 2024;12(1):166.","journal-title":"Biomark Res"},{"issue":"3","key":"4453_CR111","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/curroncol32030143","volume":"32","author":"T Moura","year":"2025","unstructured":"Moura T, et al. Breast cancer and tumor microenvironment: the crucial role of immune cells. Curr Oncol. 2025;32(3):143.","journal-title":"Curr Oncol"},{"issue":"7","key":"4453_CR112","doi-asserted-by":"crossref","first-page":"e2011792","DOI":"10.1001\/jamanetworkopen.2020.11792","volume":"3","author":"KP Lowry","year":"2020","unstructured":"Lowry KP, et al. Screening performance of digital breast tomosynthesis vs digital mammography in community practice by patient age, screening round, and breast density. JAMA Netw Open. 2020;3(7):e2011792\u20132011792.","journal-title":"JAMA Netw Open"},{"key":"4453_CR113","doi-asserted-by":"crossref","unstructured":"Gharaibeh M et al. The ability of digital breast tomosynthesis to reduce additional examinations in older women. Front Med, 2023. 10:1276434.","DOI":"10.3389\/fmed.2023.1276434"},{"key":"4453_CR114","doi-asserted-by":"crossref","first-page":"1587517","DOI":"10.3389\/fonc.2025.1587517","volume":"15","author":"AQ Khan","year":"2025","unstructured":"Khan AQ, et al. Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies. Front Oncol. 2025;15:1587517.","journal-title":"Front Oncol"},{"issue":"1","key":"4453_CR115","doi-asserted-by":"crossref","first-page":"22149","DOI":"10.1038\/s41598-024-72707-2","volume":"14","author":"I Kassis","year":"2024","unstructured":"Kassis I, et al. Detection of breast cancer in digital breast tomosynthesis with vision Transformers. Sci Rep. 2024;14(1):22149.","journal-title":"Sci Rep"},{"issue":"3","key":"4453_CR116","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.semnuclmed.2025.01.008","volume":"55","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. AI in breast cancer imaging: an update and future trends. Semin Nucl Med. 2025;55(3):358\u201370.","journal-title":"Semin Nucl Med"},{"issue":"10","key":"4453_CR117","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.diii.2019.07.012","volume":"100","author":"C Mandoul","year":"2019","unstructured":"Mandoul C, et al. Breast tomosynthesis: what do we know and where do we stand? Diagn Interv Imaging. 2019;100(10):537\u201351.","journal-title":"Diagn Interv Imaging"},{"issue":"2","key":"4453_CR118","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3348\/jksr.2025.0011","volume":"86","author":"JM Chang","year":"2025","unstructured":"Chang JM, Lee W, Bahl M. Clinical application of artificial intelligence in digital breast tomosynthesis. J Korean Soc Radiol. 2025;86(2):205\u201315.","journal-title":"J Korean Soc Radiol"},{"issue":"6","key":"4453_CR119","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/cancers12061581","volume":"12","author":"A Allegra","year":"2020","unstructured":"Allegra A, et al. Cancer and SARS-CoV-2 infection: diagnostic and therapeutic challenges. Cancers. 2020;12(6):1581.","journal-title":"Cancers"},{"key":"4453_CR120","doi-asserted-by":"crossref","first-page":"100299","DOI":"10.1016\/j.jlb.2025.100299","volume":"8","author":"S Malik","year":"2025","unstructured":"Malik S, Zaheer S. The impact of liquid biopsy in breast cancer: redefining the landscape of non-invasive precision oncology. J Liquid Biopsy. 2025;8:100299.","journal-title":"J Liquid Biopsy"},{"issue":"12","key":"4453_CR121","first-page":"e50176","volume":"15","author":"KK Adhit","year":"2023","unstructured":"Adhit KK, et al. Liquid biopsy: an evolving paradigm for Non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023;15(12):e50176.","journal-title":"Cureus"},{"issue":"1","key":"4453_CR122","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12935-025-03883-y","volume":"25","author":"D Janjua","year":"2025","unstructured":"Janjua D, et al. Redefining cancer care: Harnessing Circulating tumor cells\u2019 potential for improved diagnosis and prognosis. Cancer Cell Int. 2025;25(1):267.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4453_CR123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-025-02024-7","volume":"27","author":"HJ Zhong","year":"2025","unstructured":"Zhong HJ, et al. Advances in CTC and ctdna detection techniques: opportunities for improving breast cancer care. Breast Cancer Res. 2025;27(1):97.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4453_CR124","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","volume":"10","author":"T Thomas-Bonafos","year":"2024","unstructured":"Thomas-Bonafos T, et al. Circulating tumor cells in breast cancer: clinical validity and utility. Npj Breast Cancer. 2024;10(1):103.","journal-title":"Npj Breast Cancer"},{"issue":"5","key":"4453_CR125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4048\/jbc.2023.26.e45","volume":"26","author":"JS Ahn","year":"2023","unstructured":"Ahn JS, et al. Artificial intelligence in breast cancer diagnosis and personalized medicine. J Breast Cancer. 2023;26(5):405\u201335.","journal-title":"J Breast Cancer"},{"key":"4453_CR126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.32553\/ijmbs.v9i4.3097","volume":"9","author":"A Shahi","year":"2025","unstructured":"Shahi A, Mishra S, Rath M. Early breast Cancer - Recent advances in imaging and management. Int J Med Biomedical Stud. 2025;9:37\u201357.","journal-title":"Int J Med Biomedical Stud"},{"issue":"3","key":"4453_CR127","doi-asserted-by":"crossref","first-page":"003685042513623","DOI":"10.1177\/00368504251362350","volume":"108","author":"Y El-Tanani","year":"2025","unstructured":"El-Tanani Y, et al. Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence. Sci Prog. 2025;108(3):00368504251362350.","journal-title":"Sci Prog"},{"key":"4453_CR128","doi-asserted-by":"crossref","unstructured":"Khalid A et al. Breast Cancer Detection and Prevention Using Machine Learning. Diagnostics (Basel), 2023. 13(19).","DOI":"10.3390\/diagnostics13193113"},{"key":"4453_CR129","doi-asserted-by":"crossref","unstructured":"Chaudhary N, Dhunny AZ. An artificial intelligence model for early-stage breast cancer classification from histopathological biopsy images. Front Artif Intell, 2025. Volume 8\u20132025.","DOI":"10.3389\/frai.2025.1627876"},{"issue":"4","key":"4453_CR130","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s11831-024-10209-0","volume":"32","author":"G Bulusu","year":"2025","unstructured":"Bulusu G, et al. Cancer detection using artificial intelligence: A paradigm in early diagnosis. Arch Comput Methods Eng. 2025;32(4):2365\u2013403.","journal-title":"Arch Comput Methods Eng"},{"issue":"1","key":"4453_CR131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41698-024-00657-z","volume":"8","author":"FW Janssen","year":"2024","unstructured":"Janssen FW, et al. A comprehensive overview of liquid biopsy applications in pediatric solid tumors. Npj Precision Oncol. 2024;8(1):172.","journal-title":"Npj Precision Oncol"},{"issue":"1","key":"4453_CR132","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-025-02369-9","volume":"24","author":"A Tiwari","year":"2025","unstructured":"Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Mol Cancer. 2025;24(1):159.","journal-title":"Mol Cancer"},{"key":"4453_CR133","first-page":"927","volume":"17","author":"A Ali","year":"2025","unstructured":"Ali A, et al. Exploring AI approaches for breast cancer detection and diagnosis: A review Article. Breast Cancer (Dove Med Press). 2025;17:927\u201347.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"3","key":"4453_CR134","doi-asserted-by":"crossref","first-page":"e230318","DOI":"10.1148\/ryai.230318","volume":"6","author":"EK Park","year":"2024","unstructured":"Park EK, et al. Impact of AI for digital breast tomosynthesis on breast cancer detection and interpretation time. Radiol Artif Intell. 2024;6(3):e230318.","journal-title":"Radiol Artif Intell"},{"issue":"1","key":"4453_CR135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12880-025-01982-w","volume":"25","author":"W Hu","year":"2025","unstructured":"Hu W, et al. Performance of artificial intelligence-assisted ultrasound elastography in classifying benign and malignant breast tumors: a systematic review and meta-analysis. BMC Med Imaging. 2025;25(1):440.","journal-title":"BMC Med Imaging"},{"key":"4453_CR136","doi-asserted-by":"crossref","unstructured":"Mashekova A et al. Review of artificial intelligence techniques for breast cancer detection with different modalities: Mammography, Ultrasound, and thermography images. Bioeng (Basel), 2025. 12(10):1110.","DOI":"10.3390\/bioengineering12101110"},{"key":"4453_CR137","first-page":"100774","volume":"31","author":"A Jabbar","year":"2025","unstructured":"Jabbar A, et al. AI-optimized breast cancer prognostics: robust prediction with transformer-based lesion localization and hard voting classifier. Egypt Inf J. 2025;31:100774.","journal-title":"Egypt Inf J"},{"key":"4453_CR138","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.inffus.2021.07.016","volume":"77","author":"G Yang","year":"2022","unstructured":"Yang G, Ye Q, Xia J. Unbox the black-box for the medical explainable AI via multi-modal and multi-centre data fusion: A mini-review, two showcases and beyond. Inform Fusion. 2022;77:29\u201352.","journal-title":"Inform Fusion"},{"key":"4453_CR139","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.aspetd.2025.100012","volume":"1","author":"JV Eapen","year":"2025","unstructured":"Eapen JV, et al. Integrative strategies in breast cancer therapy: conventional approaches, emerging advances, and future challenges. ASPET Discovery. 2025;1:100012.","journal-title":"ASPET Discovery"},{"key":"4453_CR140","doi-asserted-by":"crossref","unstructured":"Dynarowicz K et al. Breast cancer treatments: drugs targeting the PI3K\/AKT\/mTOR Pathway, TNBC therapy and future directions: A review. Life (Basel), 2025. 15(10):1583.","DOI":"10.3390\/life15101583"},{"key":"4453_CR141","doi-asserted-by":"crossref","unstructured":"Mukherjee A, Bandyopadhyay D. Targeted therapy in breast cancer: advantages and advancements of Antibody-Drug Conjugates, a type of Chemo-Biologic hybrid drugs. Cancers (Basel), 2024. 16(20):3517.","DOI":"10.3390\/cancers16203517"},{"key":"4453_CR142","doi-asserted-by":"crossref","unstructured":"Mercogliano MF et al. Emerging targeted therapies for HER2-Positive breast cancer. Cancers (Basel), 2023. 15(7):1987.","DOI":"10.3390\/cancers15071987"},{"issue":"9","key":"4453_CR143","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"4453_CR144","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/oncolo\/oyae064","volume":"29","author":"A LeVee","year":"2024","unstructured":"LeVee A, et al. Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis. Oncologist. 2024;29(7):566\u201374.","journal-title":"Oncologist"},{"issue":"1","key":"4453_CR145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","volume":"14","author":"R Ran","year":"2025","unstructured":"Ran R, et al. Immunotherapy in breast cancer: current landscape and emerging trends. Experimental Hematol Oncol. 2025;14(1):77.","journal-title":"Experimental Hematol Oncol"},{"key":"4453_CR146","doi-asserted-by":"crossref","unstructured":"Yu T, et al. Endocrine therapy resistance of breast cancer: important role of G protein-coupled Estrogen receptor (GPER) and new therapeutic strategies. Genes & Diseases; 2025. p. 101716.","DOI":"10.1016\/j.gendis.2025.101716"},{"key":"4453_CR147","doi-asserted-by":"crossref","unstructured":"Kim N, Lukong KE. Treating ER-positive breast cancer: a review of the current FDA-approved serms and SERDs and their mechanisms of action. Oncol Reviews, 2025. 19:1564642.","DOI":"10.3389\/or.2025.1564642"},{"issue":"1","key":"4453_CR148","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s11671-025-04308-5","volume":"20","author":"NR Ramayanam","year":"2025","unstructured":"Ramayanam NR, et al. Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discover Nano. 2025;20(1):111.","journal-title":"Discover Nano"},{"key":"4453_CR149","doi-asserted-by":"crossref","unstructured":"Arafat M et al. Nanomedicines: emerging platforms in smart chemotherapy Treatment-A recent review. Pharmaceuticals (Basel), 2024. 17(3):315.","DOI":"10.3390\/ph17030315"},{"issue":"1","key":"4453_CR150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12935-025-03731-z","volume":"25","author":"AE Basyoni","year":"2025","unstructured":"Basyoni AE, et al. Harnessing exosomes for targeted drug delivery systems to combat brain cancer. Cancer Cell Int. 2025;25(1):150.","journal-title":"Cancer Cell Int"},{"key":"4453_CR151","doi-asserted-by":"crossref","first-page":"1093607","DOI":"10.3389\/fimmu.2022.1093607","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2022;13:1093607.","journal-title":"Front Immunol"},{"issue":"1","key":"4453_CR152","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12943-025-02372-0","volume":"24","author":"JJJ Liu","year":"2025","unstructured":"Liu JJJ, et al. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer. 2025;24(1):166.","journal-title":"Mol Cancer"},{"issue":"18","key":"4453_CR153","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.3390\/cancers14184543","volume":"14","author":"M G\u00e1mez-Chiachio","year":"2022","unstructured":"G\u00e1mez-Chiachio M, Sarri\u00f3 D, Moreno-Bueno G. Novel therapies and strategies to overcome resistance to Anti-HER2-Targeted drugs. Cancers. 2022;14(18):4543.","journal-title":"Cancers"},{"issue":"1","key":"4453_CR154","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol. 2025;16(1):578.","journal-title":"Discov Oncol"},{"issue":"5","key":"4453_CR155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mc.23893","volume":"64","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, et al. Evaluation and comparison of prognostic multigene tests in Early-Stage breast cancer: which is the most effective? A literature review exploring clinical utility to enhance therapeutic management in luminal patients. Mol Carcinog. 2025;64(5):789\u2013800.","journal-title":"Mol Carcinog"},{"key":"4453_CR156","unstructured":"Ohnstad, H.O., et al., Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer\u2014a prospective national multicentre study (EMIT-1). ESMO Open, 2024. 9(6)."},{"key":"4453_CR157","doi-asserted-by":"crossref","unstructured":"Rezayi S, R.N.K. S, and, Saeedi S. Effectiveness of Artificial Intelligence for Personalized Medicine in Neoplasms: A Systematic Review. Biomed Res Int, 2022. 2022: p. 7842566.","DOI":"10.1155\/2022\/7842566"},{"key":"4453_CR158","doi-asserted-by":"crossref","unstructured":"Zhang J et al. Deep learning\u2013driven multi-omics analysis: enhancing cancer diagnostics and therapeutics. Brief Bioinform, 2025. 26(4):bbaf440.","DOI":"10.1093\/bib\/bbaf440"},{"issue":"3","key":"4453_CR159","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clbc.2024.12.013","volume":"25","author":"YC Lin","year":"2025","unstructured":"Lin YC, et al. Safety and feasibility of robotic Nipple-Sparing mastectomy with immediate Direct-to-Implant Reconstruction - Insights from the one of the largest centers in Asia. Clin Breast Cancer. 2025;25(3):277\u201382.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"4453_CR160","first-page":"e87972","volume":"17","author":"T Branco","year":"2025","unstructured":"Branco T, Rodrigues A, Martins AR. Robotics in breast surgery: current Advantages, Disadvantages, and applications. Cureus. 2025;17(7):e87972.","journal-title":"Cureus"},{"issue":"3","key":"4453_CR161","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4048\/jbc.2025.0030","volume":"28","author":"JM Ryu","year":"2025","unstructured":"Ryu JM, et al. Consensus statement on robotic nipple sparing mastectomy expert panel. J Breast Cancer. 2025;28(3):180\u201392.","journal-title":"J Breast Cancer"},{"issue":"8","key":"4453_CR162","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1245\/s10434-025-17546-9","volume":"32","author":"MJ Silverstein","year":"2025","unstructured":"Silverstein MJ, et al. Intraoperative radiation therapy (IORT) for breast cancer: the final analysis of a prospective cohort of 1828 cases. Ann Surg Oncol. 2025;32(8):5563\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4453_CR163","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12893-021-01427-5","volume":"22","author":"V Zangouri","year":"2022","unstructured":"Zangouri V, et al. Intraoperative radiation therapy for early stage breast cancer. BMC Surg. 2022;22(1):26.","journal-title":"BMC Surg"},{"issue":"8","key":"4453_CR164","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jfma.2022.01.015","volume":"121","author":"W-K Chuang","year":"2022","unstructured":"Chuang W-K, et al. Comparison between the use of hypofractionated and conventionally fractionated radiotherapy in early breast cancer: A single-center real-world study in Taiwan. J Formos Med Assoc. 2022;121(8):1588\u201395.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"4453_CR165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13063-023-07851-7","volume":"25","author":"BS Yadav","year":"2024","unstructured":"Yadav BS, et al. HYPofractionated adjuvant radiotherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial. Trials. 2024;25(1):21.","journal-title":"Trials"},{"issue":"4","key":"4453_CR166","first-page":"e81702","volume":"17","author":"DK Panda","year":"2025","unstructured":"Panda DK, Das SR, Kumar S. Artificial intelligence (AI)-Driven adaptive motion management in helical and robotic radiotherapy: Innovations, Challenges, and future directions. Cureus. 2025;17(4):e81702.","journal-title":"Cureus"},{"key":"4453_CR167","doi-asserted-by":"crossref","unstructured":"Duke K, Papanikolaou N. Artificial intelligence in radiation therapy: from imaging to delivery\u2014a comprehensive review. BJR|Artificial Intell, 2025. 2(1):ubaf012.","DOI":"10.1093\/bjrai\/ubaf012"},{"issue":"1","key":"4453_CR168","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13014-025-02697-6","volume":"20","author":"F Preziosi","year":"2025","unstructured":"Preziosi F, et al. AI-driven online adaptive radiotherapy in prostate cancer treatment: considerations on activity time and dosimetric benefits. Radiat Oncol. 2025;20(1):116.","journal-title":"Radiat Oncol"},{"key":"4453_CR169","doi-asserted-by":"crossref","unstructured":"Webster M et al. New Approaches in Radiotherapy. Cancers, 2025. 17(12): p. 1980.","DOI":"10.3390\/cancers17121980"},{"issue":"1","key":"4453_CR170","doi-asserted-by":"crossref","first-page":"14312","DOI":"10.1038\/s41598-022-18342-1","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. Sci Rep. 2022;12(1):14312.","journal-title":"Sci Rep"},{"issue":"4","key":"4453_CR171","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.52711\/0974-360X.2024.00303","volume":"17","author":"S Kumar","year":"2024","unstructured":"Kumar S, et al. Traumatic brain injury: role in induction and progression of neurodegenerative disorders. Res J Pharm Technol. 2024;17(4):1909\u201315.","journal-title":"Res J Pharm Technol"},{"issue":"12","key":"4453_CR172","first-page":"6087","volume":"16","author":"S Kumar","year":"2023","unstructured":"Kumar S, et al. Applications of polymeric nanoparticle in nose to brain drug delivery. Res J Pharm Technol. 2023;16(12):6087\u201394.","journal-title":"Res J Pharm Technol"},{"issue":"5","key":"4453_CR173","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","volume":"30","author":"S Shil","year":"2025","unstructured":"Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025;30(5):1075\u201392.","journal-title":"Heart Fail Rev"},{"key":"4453_CR174","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.glmedi.2024.100099","volume":"3","author":"DB Olawade","year":"2024","unstructured":"Olawade DB, et al. Enhancing mental health with artificial intelligence: current trends and future prospects. J Med Surg Public Health. 2024;3:100099.","journal-title":"J Med Surg Public Health"},{"issue":"1","key":"4453_CR175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s44184-023-00033-y","volume":"2","author":"RR Bond","year":"2023","unstructured":"Bond RR, et al. Digital transformation of mental health services. Npj Mental Health Res. 2023;2(1):13.","journal-title":"Npj Mental Health Res"},{"issue":"3","key":"4453_CR176","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4048\/jbc.2023.26.e28","volume":"26","author":"YH Hong","year":"2023","unstructured":"Hong YH, et al. Fertility preservation in young women with breast cancer: A review. J Breast Cancer. 2023;26(3):221\u201342.","journal-title":"J Breast Cancer"},{"key":"4453_CR177","doi-asserted-by":"crossref","unstructured":"Smith KL et al. Advances in fertility preservation for young women with cancer. Am Soc Clin Oncol Educational Book, 2018;38:27\u201337.","DOI":"10.1200\/EDBK_208301"},{"issue":"5","key":"4453_CR178","first-page":"614","volume":"17","author":"ED Crawford","year":"2003","unstructured":"Crawford ED. A 42-year-old woman with breast cancer. Oncol (Williston Park). 2003;17(5):614. discussion 615\u2009\u2013\u200920.","journal-title":"Oncol (Williston Park)"},{"issue":"1","key":"4453_CR179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000325746","volume":"15","author":"KA Goddard","year":"2012","unstructured":"Goddard KA, et al. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics. 2012;15(1):1\u201310.","journal-title":"Public Health Genomics"},{"issue":"9","key":"4453_CR180","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1016\/j.radcr.2023.07.001","volume":"18","author":"BJ McFarland","year":"2023","unstructured":"McFarland BJ, Luo A, Wang X. Male breast cancer: report of two cases with bloody nipple discharge. Radiol Case Rep. 2023;18(9):3323\u201330.","journal-title":"Radiol Case Rep"},{"key":"4453_CR181","doi-asserted-by":"crossref","unstructured":"Pang L et al. Bone metastasis of breast cancer: molecular mechanisms and therapeutic strategies. Cancers (Basel), 2022. 14(23):5727.","DOI":"10.3390\/cancers14235727"},{"key":"4453_CR182","doi-asserted-by":"crossref","unstructured":"Khalil N, Fowler C. Misconceptions surrounding pregnancy-associated breast cancer. BMJ Case Rep, 2018. 11(1):e226719.","DOI":"10.1136\/bcr-2018-226719"},{"issue":"5","key":"4453_CR183","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000531612","volume":"18","author":"P Gebhart","year":"2023","unstructured":"Gebhart P, et al. Novo BRCA1 pathogenic variant in a 29-Year-Old woman with Triple-Negative breast cancer. Breast Care (Basel). 2023;18(5):412\u20136. de.","journal-title":"Breast Care (Basel)"},{"issue":"18","key":"4453_CR184","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.3390\/cancers13184572","volume":"13","author":"T Qing","year":"2021","unstructured":"Qing T, et al. Genomic determinants of homologous recombination deficiency across human cancers. Cancers. 2021;13(18):4572.","journal-title":"Cancers"},{"issue":"825","key":"4453_CR185","doi-asserted-by":"crossref","first-page":"eadf2670","DOI":"10.1126\/scisignal.adf2670","volume":"17","author":"EC Erickson","year":"2024","unstructured":"Erickson EC, et al. Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Sci Signal. 2024;17(825):eadf2670.","journal-title":"Sci Signal"},{"key":"4453_CR186","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","volume":"10","author":"R Zhou","year":"2019","unstructured":"Zhou R, et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149.","journal-title":"Front Immunol"},{"key":"4453_CR187","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.adcanc.2023.100090","volume":"7","author":"A Dey","year":"2023","unstructured":"Dey A, et al. Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. Adv Cancer Biology - Metastasis. 2023;7:100090.","journal-title":"Adv Cancer Biology - Metastasis"},{"issue":"4","key":"4453_CR188","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.7150\/jca.54095","volume":"12","author":"S Toulouie","year":"2021","unstructured":"Toulouie S, Johanning G, Shi Y. Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges. J Cancer. 2021;12(4):1212\u20139.","journal-title":"J Cancer"},{"key":"4453_CR189","first-page":"117693512513712","volume":"24","author":"N Najar Najafi","year":"2025","unstructured":"Najar Najafi N, Hajihassani H, Azimzadeh Irani M. The impact of artificial intelligence on cancer diagnosis and treatment: A review. Cancer Inf. 2025;24:11769351251371273.","journal-title":"Cancer Inf"},{"key":"4453_CR190","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.2147\/DDDT.S509769","volume":"19","author":"FG Albani","year":"2025","unstructured":"Albani FG, et al. Artificial Intelligence-Driven innovations in oncology drug discovery: transforming traditional pipelines and enhancing drug design. Drug Des Devel Ther. 2025;19:5685\u2013707.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4453_CR191","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","volume":"23","author":"J Wang","year":"2025","unstructured":"Wang J, et al. The clinical application of artificial intelligence in cancer precision treatment. J Translational Med. 2025;23(1):120.","journal-title":"J Translational Med"},{"key":"4453_CR192","doi-asserted-by":"crossref","first-page":"1082884","DOI":"10.3389\/fdgth.2022.1082884","volume":"4","author":"S Bhattacharya","year":"2022","unstructured":"Bhattacharya S, et al. Expanding the horizon for breast cancer screening in India through artificial intelligent technologies -A mini-review. Front Digit Health. 2022;4:1082884.","journal-title":"Front Digit Health"},{"issue":"4","key":"4453_CR193","first-page":"e57619","volume":"16","author":"ZS Rentiya","year":"2024","unstructured":"Rentiya ZS, et al. Revolutionizing breast cancer detection with artificial intelligence (AI) in radiology and radiation oncology: A systematic review. Cureus. 2024;16(4):e57619.","journal-title":"Cureus"},{"issue":"1","key":"4453_CR194","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","volume":"14","author":"N Li","year":"2025","unstructured":"Li N, et al. Antibody-drug conjugates in breast cancer: current evidence and future directions. Experimental Hematol Oncol. 2025;14(1):41.","journal-title":"Experimental Hematol Oncol"},{"issue":"4","key":"4453_CR195","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/pharmaceutics15041242","volume":"15","author":"MA Subhan","year":"2023","unstructured":"Subhan MA, Torchilin VP. Advances in targeted therapy of breast cancer with Antibody-Drug conjugate. Pharmaceutics. 2023;15(4):1242.","journal-title":"Pharmaceutics"},{"issue":"34","key":"4453_CR196","doi-asserted-by":"crossref","first-page":"27795","DOI":"10.1039\/D5RA03747F","volume":"15","author":"D Khorsandi","year":"2025","unstructured":"Khorsandi D, et al. Bridging technology and medicine: artificial intelligence in targeted anticancer drug delivery. RSC Adv. 2025;15(34):27795\u2013815.","journal-title":"RSC Adv"},{"key":"4453_CR197","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.mtbio.2025.102660","volume":"36","author":"A Younas","year":"2026","unstructured":"Younas A, et al. Recent advances in cancer nanomedicine: from smart targeting to personalized therapeutics - pioneering a new era in precision oncology. Mater Today Bio. 2026;36:102660.","journal-title":"Mater Today Bio"},{"issue":"1","key":"4453_CR198","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s44301-025-00008-2","volume":"1","author":"A Fortune","year":"2025","unstructured":"Fortune A, et al. Nanotechnology in medicine: a double-edged sword for health outcomes. Health Nanatechnol. 2025;1(1):9.","journal-title":"Health Nanatechnol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04453-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:06:36Z","timestamp":1769249196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04453-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":198,"alternative-id":["4453"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04453-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}